About Dr. Fein
Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.
Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment, to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.
Dr. Fein’s popular and influential Drug Channels blog is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, Fortune, Drug Benefit News, and many others.
Dr. Fein also is a popular speaker. He inspires his audiences to think strategically with content-rich and entertaining keynote presentations.
Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.
Dr. Fein in the News
Hospitals Fight to Keep Medicare Drug Subsidies The Wall Street Journal
Big Box Pharmacy on the Rise Drug Topics
Walgreens deal offers no lasting relief to Rite Aid The New York Times
Asembia Summit Illustrates Growth in Specialty Pharmacy Specialty Pharmacy Times
Specialty Pharmacy: Where Are We Now and Where Are We Headed? Specialty Pharmacy Times
Amazon’s bid for Whole Foods sparks speculation on what it might gobble up next The Washington Post
Amazon may be mulling pharmacy market entry Chain Drug Review
What Amazon could do to the business of selling prescription drugs The Washington Post
Why Specialty Drug Prices Will Continue to Soar Drug Topics
Express Scripts to Offer Cheaper Drugs for Uninsured Customers The New York Times
Outlook: New landscape for drug chains? Chain Drug Review